GHRH Antagonists Suppress Papillary Thyroid Cancer Growth by Inhibiting MMP-2
Background
The aggressive nature of papillary thyroid cancer (PTC), the most common form of thyroid malignancy, often involves uncontrolled cell proliferation and metastasis. Previous research has indicated that Growth Hormone-Releasing Hormone (GHRH), a peptide hormone primarily known for stimulating growth hormone release, can also act as a growth factor for various cancers, including thyroid tumors. However, the precise role of GHRH receptors (pGHRH-R) in PTC and the potential for GHRH antagonists to modulate tumor invasiveness through specific pathways like Matrix Metalloproteinase-2 (MMP-2) remained largely unexplored. This study aimed to investigate the expression of pGHRH-R in human PTC cells and evaluate whether GHRH antagonists could reduce tumor invasiveness by targeting MMP-2 activity.
Results
The study confirmed the significant expression of pGHRH-R in all human papillary thyroid cancer cell lines tested, establishing a direct target for GHRH antagonists. Treatment with GHRH antagonists resulted in a dose-dependent reduction in both cell proliferation and MMP-2 expression and activity. For instance, MIA-602 at a concentration of 5 µM significantly inhibited cell proliferation by 48% (p<0.001) after 48 hours compared to untreated control cells. Furthermore, this same treatment led to a remarkable 65% decrease in MMP-2 mRNA expression and a 55% reduction in MMP-2 enzymatic activity (p<0.001). The most significant finding was that MIA-602 at 5 µM caused a 2.3-fold reduction in the invasive capacity of PTC cells in a transwell invasion assay, directly correlating with the observed decrease in MMP-2 activity. Another antagonist, MIA-690, also demonstrated a substantial 35% reduction in cell proliferation and a 40% decrease in MMP-2 protein levels at 10 µM (p<0.01), reinforcing the therapeutic potential of targeting the GHRH pathway in PTC.
Why It Matters
These findings are highly significant as they identify pGHRH-R as a viable therapeutic target in papillary thyroid cancer and demonstrate the potent anti-proliferative and anti-invasive effects of GHRH antagonists. The observed reduction in MMP-2 (Matrix Metalloproteinase-2), an enzyme crucial for tumor invasion and metastasis, suggests a novel mechanism by which these antagonists could impede PTC progression. This research provides a strong preclinical rationale for developing GHRH antagonists as a new class of targeted agents for PTC. Ultimately, these promising results could lead to the development of innovative clinical strategies to improve outcomes for patients with aggressive papillary thyroid cancer, potentially moving towards Phase I and II human trials to evaluate safety and efficacy.